No Data
No Data
Huazhao Zhongtian Pharmaceutical-B (02563.HK) has appointed Da Xin International (Hong Kong) as the new auditor.
On April 25, Ge Long Hui announced that Hua Hao Zhong Tian Pharmaceutical-B (02563.HK) stated that the auditing firm KPMG has agreed to resign as the company's auditor at the request of the Board of Directors, effective April 24, 2025. Upon the recommendation of the audit committee, the Board of Directors has resolved to propose the appointment of Daxin International (Hong Kong) Accountancy Limited as the new auditor.
Huakao Zhongtian Medicine-B (02563): Ran Dong resigned as Independent Non-Executive Director.
HuaHao ZhongTian Pharmaceutical-B (02563) announced that on April 10, 2025, Ran Dong will focus on handling Other...
Huahao Zhongtian Pharmaceutical-B (02563): Tang Jin has been appointed as a member of the Audit Committee under the Board of Directors.
Huahao Zhongtian Pharmaceutical-B (02563) announced that due to the company’s audit committee regarding Ms. Qi from March 2025...
Huahao Zhongtian Pharmaceutical-B (02563.HK) will be suspended from trading starting April 1.
Gelonghui, April 1丨 Huahao Zhongtian Pharmaceutical-B (02563.HK) announced that since the company was unable to publish its 2024 annual results on or before March 31, 2025, it will apply for the suspension of its shares from trading on the Stock Exchange starting at 9:00 AM on April 1, 2025, pending the publication of the 2024 annual results.
BIOSTAR PHARM-B: DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS; AND POSSIBLE SUSPENSION OF TRADING
Huahao Zhongtian Pharmaceuticals-B (02563): Qi Jingyao resigns as Independent Non-Executive Director.
Hua Hao Zhong Tian Pharmaceutical-B (02563) announced that Ms. Qi Jingyao has resigned from the company as an independent director to focus on handling Other personal matters.